Carolina Solis-Herrera
Overview
Explore the profile of Carolina Solis-Herrera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
870
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Solis-Herrera C, Qin Y, Honka H, Cersosimo E, Triplitt C, Neppala S, et al.
Diabetes
. 2024 Oct;
74(1):43-52.
PMID: 39446133
Article Highlights:
2.
Escobar Vasco M, Fantaye S, Raghunathan S, Solis-Herrera C
Diabetes Obes Metab
. 2024 Jul;
26(10):4135-4146.
PMID: 39021345
Chronic kidney disease (CKD) represents a global health concern, associated with an increased risk of cardiovascular morbidity and mortality and decreased quality of life. Many patients with type 1 diabetes...
3.
Chen X, Tripathy D, Chilton R, Hansis-Diarte A, Salehi M, Solis-Herrera C, et al.
Diabetes
. 2024 Mar;
73(6):896-902.
PMID: 38512770
Article Highlights:
4.
Solis-Herrera C, Kane M, Triplitt C
Clin Diabetes
. 2024 Jan;
42(1):74-86.
PMID: 38230324
Oral administration of peptide therapeutics faces challenges because of the distinct environment of the gastrointestinal tract. An oral formulation of semaglutide, a glucagon-like peptide 1 receptor agonist, was approved by...
5.
Zhao S, Li N, Xiong W, Li G, He S, Zhang Z, et al.
Diabetes
. 2023 Nov;
73(2):197-210.
PMID: 37935033
Article Highlights:
6.
Solis-Herrera C, Triplitt C
Diabetes Obes Metab
. 2023 Oct;
26(2):417-430.
PMID: 37885354
Chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) is a major health challenge associated with a disproportionately high burden of end-stage renal disease, cardiovascular disease and death....
7.
Cersosimo E, Alatrach M, Solis-Herrera C, Baskoy G, Adams J, Hansis-Diarte A, et al.
J Clin Endocrinol Metab
. 2023 Jul;
109(1):161-170.
PMID: 37481263
Context: This study addresses the development of a new glucoregulatory mechanism in type 2 diabetes (T2D) patients treated with SGLT-2 inhibitors, which is independent of glucose, insulin and glucagon. The...
8.
Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes
Moody A, Molina-Wilkins M, Clarke G, Merovci A, Solis-Herrera C, Cersosimo E, et al.
Diabetes Obes Metab
. 2022 Oct;
25(2):426-434.
PMID: 36204991
Aims: To examine the effect of pioglitazone on epicardial (EAT) and paracardial adipose tissue (PAT) and measures of diastolic function and insulin sensitivity in patients with type 2 diabetes mellitus...
9.
Alatrach M, Agyin C, Solis-Herrera C, Lavryneko O, Adams J, Gastaldelli A, et al.
Diabetes Care
. 2022 Mar;
45(6):1372-1380.
PMID: 35235659
Objective: To examine the effect of SGLT2 inhibitors (SGLT2i) on endogenous glucose production (EGP) in patients with type 2 diabetes after an oral glucose load. Research Design And Methods: Forty-eight...
10.
Solis-Herrera C, Cersosimo E, Triplitt C
Diabetes Spectr
. 2021 Sep;
34(3):248-256.
PMID: 34511851
Type 2 diabetes management continues to increase in complexity as more pharmacologic medication classes become available and high-quality clinical trials are completed. Because many antihyperglycemic agents could be appropriate for...